Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors.

Hayato S, Hamuro L, Shimizu T, Yonemori K, Nishio S, Yunokawa M, Yoshida T, Nishio M, Matsumoto K, Takehara K, Hasegawa K, Kozuki T, Hirashima Y, Kato H, Miura T, Nomoto M, Zhao Y, Zhu L, Yasuda S

Open source

DOI
10.1002/jcph.6187
Published
2025 Jun
Container
Journal of clinical pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/jcph.6187,
  title = {Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors.},
  author = {Hayato S and Hamuro L and Shimizu T and Yonemori K and Nishio S and Yunokawa M and Yoshida T and Nishio M and Matsumoto K and Takehara K and Hasegawa K and Kozuki T and Hirashima Y and Kato H and Miura T and Nomoto M and Zhao Y and Zhu L and Yasuda S},
  year = {2025},
  journal = {Journal of clinical pharmacology},
  doi = {10.1002/jcph.6187},
  url = {https://doi.org/10.1002/jcph.6187}
}

RIS

TY  - JOUR
TI  - Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors.
AU  - Hayato S
AU  - Hamuro L
AU  - Shimizu T
AU  - Yonemori K
AU  - Nishio S
AU  - Yunokawa M
AU  - Yoshida T
AU  - Nishio M
AU  - Matsumoto K
AU  - Takehara K
AU  - Hasegawa K
AU  - Kozuki T
AU  - Hirashima Y
AU  - Kato H
AU  - Miura T
AU  - Nomoto M
AU  - Zhao Y
AU  - Zhu L
AU  - Yasuda S
PY  - 2025
JO  - Journal of clinical pharmacology
DO  - 10.1002/jcph.6187
UR  - https://doi.org/10.1002/jcph.6187
ER  - 

APA

S, H., L, H., T, S., K, Y., S, N., M, Y., T, Y., M, N., K, M., K, T., K, H., T, K., Y, H., H, K., T, M., M, N., Y, Z., L, Z., & S, Y. (2025). Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors.. Journal of clinical pharmacology. https://doi.org/10.1002/jcph.6187

Source records